Advisory panel votes pressure FDA to allow access to compounded peptides
An FDA advisory committee has recommended that several unapproved peptides be added to the agency’s 503A bulks list, despite FDA staff expressing concerns about the compounds’ characterization, safety and supporting evidence. The recommendation follows growing interest in compounded peptides and renewed attention to how the FDA regulates products that fall outside the traditional drug approval pathway.
The committee’s vote raises broader questions about the relationship between drug compounding, clinical evidence and FDA oversight, while setting the stage for the agency’s next regulatory decisions.
This AgencyIQ analysis examines the policy, regulatory and practical implications of the advisory committee’s recommendations and what stakeholders should watch as the FDA determines its next steps.
Fill out the form to read the full analysis.
Required *